Medikamentöse Therapie des frühen Mammakarzinoms
Authors:
- 10 December 2025
- journal article
- research article
- Published by Springer Nature in Die Onkologie
- Vol. 32 (1) , 100-109
Abstract
No abstract availableKeywords
This publication has 30 references indexed in Scilit:
- Systematic literature review and trial-level meta-analysis of aromatase inhibitors vs tamoxifen in patients with HR+/HER2− early breast cancerThe Breast, 2025
- A phase III trial of adjuvant ribociclib plus endocrine therapy versus endocrine therapy alone in patients with HR-positive/HER2-negative early breast cancer: final invasive disease-free survival results from the NATALEE trialAnnals of Oncology, 2024
- LBA13 Adjuvant ribociclib (RIB) plus nonsteroidal aromatase inhibitor (NSAI) in patients (Pts) with HR+/HER2− early breast cancer (EBC): 4-year outcomes from the NATALEE trialAnnals of Oncology, 2024
- LBA11 Neoadjuvant nivolumab/relatlimab or nivolumab/ipilimumab in triple negative breast cancer with high tumor-infiltrating lymphocytes (TILs)Annals of Oncology, 2024
- Immune Checkpoint Inhibitor Use During Pregnancy and Outcomes in Pregnant Individuals and NewbornsJAMA Network Open, 2024
- Disease-free survival as a surrogate for overall survival in HR+/HER2– early breast cancer: A correlation analysisEuropean Journal of Cancer, 2024
- Adjuvant paclitaxel and trastuzumab for node-negative, HER2-positive breast cancer: final 10-year analysis of the open-label, single-arm, phase 2 APT trialThe Lancet Oncology, 2023
- Moderate hypofractionation remains the standard of care for whole-breast radiotherapy in breast cancer: Considerations regarding FAST and FAST-ForwardStrahlentherapie und Onkologie, 2021
- Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trialThe Lancet, 2020
- Inter‐laboratory and inter‐observer reproducibility of immunohistochemical assessment of the Ki‐67 labelling index in a large multi‐centre trialThe Journal of Pathology, 2002